New study seeks better treatment clues for aggressive breast cancer
NCT ID NCT06291064
Summary
This study aims to see how well a specific chemotherapy combination works for Nigerian women with triple-negative breast cancer, a particularly aggressive form. Researchers will measure how many women have no detectable cancer after treatment and will also look for signals in the blood that might predict if the chemotherapy will work. The goal is to improve treatment outcomes and find better ways to identify patients who might not respond to standard therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lagos State University Teaching Hospital
RECRUITINGIkeja, Lagos, 100271, Nigeria
Contact Phone: •••-•••-••••
Contact
Contact Phone: •••-•••-••••
-
Lagos University Teaching Hospital
RECRUITINGYaba, Lagos, 100254, Nigeria
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-••••
Contact
-
Obafemi Awolowo University Teaching Hospitals Complex
RECRUITINGIle-Ife, Osun State, 220005, Nigeria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Ibadan Hospital
RECRUITINGIbadan, Oyo State, 200285, Nigeria
Contact Phone: •••-•••-••••
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.